Core Insights - Inventiva has made significant progress in its clinical program and financial position during the first half of 2025, particularly in its Phase 3 clinical trial for MASH [2][23] - The company reported revenues of €4.5 million for the first half of 2025, a substantial increase from €41,000 in the same period of 2024 [4][11] - A net loss of €175.9 million was recorded for the first half of 2025, compared to a net loss of €49.0 million in the first half of 2024 [11][12] Financial Performance - Revenues for the first half of 2025 were primarily driven by a €10 million milestone payment from Chia Tai Tianqing Pharmaceutical Group and €5 million in credit notes under a license agreement [5] - Other income decreased to €1.2 million in the first half of 2025 from €2.7 million in the same period of 2024, attributed to changes in R&D tax credit eligibility [6] - Research and development expenses were €44.9 million, down 4% from €46.8 million in the first half of 2024, reflecting a decrease in costs related to discontinued preclinical programs [7] Cash Position - As of June 30, 2025, cash and cash equivalents totaled €146.7 million, including €24.6 million in short-term deposits, with a cash runway projected until the end of Q3 2026 [8][16] - The company generated €104.8 million from financing activities in the first half of 2025, primarily from the second tranche of structured financing [14] Corporate Developments - A leadership transition occurred with the appointment of Jason Campagna as President of R&D and Chief Medical Officer [18] - The company received authorization for a workforce reduction plan, which began implementation in May 2025 [18] - The completion of enrollment for the pivotal Phase 3 clinical trial, NATiV3, was announced on April 1, 2025 [18] Future Outlook - Topline results from the NATiV3 trial are expected in the second half of 2026 [20] - The company plans to raise additional funds for long-term objectives, including potential public offerings or strategic partnerships [17]

Core Insights - Aclaris Therapeutics is entering a transformative multi-year period with significant milestones expected in 2025 and 2026, focusing on immuno-inflammatory diseases [2] - The company has extended its expected cash runway through the first half of 2028, allowing for continued execution of its clinical programs [2][11] - Aclaris has received positive Phase 2 results from its Chinese partner CTTQ, indicating enhanced potency of its investigational drug bosakitug (ATI-045) [3][5] - The U.S. FDA has cleared the Investigational New Drug (IND) application for ATI-052, a bispecific antibody, paving the way for its clinical trials [7] Pipeline Developments - Bosakitug (ATI-045) is an investigational anti-TSLP monoclonal antibody, with plans to initiate a placebo-controlled Phase 2 trial in atopic dermatitis (AD) in Q2 2025 [5] - ATI-2138, an oral ITK/JAK3 inhibitor, is also set for new clinical trials, with top-line results from a Phase 2a trial in AD expected in June 2025 [6] - Aclaris intends to seek partnerships for the global development of bosakitug in respiratory indications, while maintaining focus on dermatological applications [5] Financial Performance - For Q1 2025, Aclaris reported a net loss of $15.1 million, an improvement from a loss of $16.9 million in Q1 2024 [12] - Total revenue for Q1 2025 was $1.5 million, down from $2.4 million in the same period last year, primarily due to a decrease in royalty payments [12] - Research and development expenses increased to $11.6 million in Q1 2025, driven by costs associated with the bosakitug program [13] Corporate Updates - Aclaris has appointed Dr. Jesse W. Hall as Chief Medical Officer, bringing extensive experience in drug development [10] - The company is exploring additional non-dilutive financing opportunities following the lifting of an injunction against Sun Pharmaceuticals, which may provide a financial asset for monetization [11]